Exiqon, a privately held Danish biotech company, has granted a license to Roche Diagnostics for use of the Universal ProbeLibrary that is based on Exiqon's proprietary LNA detection technology.
Subscribe to our email newsletter
Roche Diagnostics will develop its new product line for RealTime ready qPCR assays with the Universal ProbeLibrary. The financial details of the agreement including commercial milestone payments and royalties on future product sales are not disclosed.
Lars Kongsbak, president and CEO of Exiqon, said: “This extension of our successful partnership with Roche allows for the application of Exiqon’s LNA detection technology in the new and fast-growing market for ready-to-use and customizable RealTime PCR products. We are exited to have Roche Diagnostics, who is a leader in the RealTime PCR market, embrace the LNA detection technology in their new product offering.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.